To enhance the activity of this drug, a phase I study is ongoing that is evaluating MCLA-129 in combination with befotertinib (a third-generation EGFR-TKI) in Cohort B, which includes patients with advanced NSCLC with resistance to third-generation EGFR-TKIs (NCT06015568). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.